Anyone either celebrating or fearing the start of a Hepatitis C drug price war should take a break from the excitement to consider that a far more nuanced and profound game is at hand, one where the rules of tacit collusion (the legal kind) constrain price erosion—and each new entrant with a “good enough” drug … Continue reading “Hepatitis C Commercial Game Theory”
Author: Peter Kolchinsky
Peter Kolchinsky, PhD is a founding Partner and Portfolio Manager at RA Capital. Mr. Kolchinsky is active in both public and private investments across drugs, medical devices, diagnostics, and life-science tools. He authored the e-book “the Entrepreneur’s Guide to a Biotech Startup”, serves on the board of the American Fertility Association, and is a board member of several private healthcare companies.
In the past, he has served on the Board of Global Science and Technology for the National Academies of Sciences. Mr. Kolchinsky received a Ph.D. in Virology from Harvard University. His doctoral work involved studies of the mechanism by which HIV infects cells. He received a Bachelors degree from Cornell University.
Rethinking Venture Philanthropy After the Kalydeco Windfall
The Cystic Fibrosis (CF) Foundation’s big win in venture philanthropy can fuel constructive competition among companies developing innovative CF drugs, benefiting both patients and the healthcare system by increasing future treatment options and reducing their cost. CF is a fatal genetic disease affecting around 30,000 people in the U.S. that is caused by mutations in … Continue reading “Rethinking Venture Philanthropy After the Kalydeco Windfall”
How to Save $200 Billion and Cure Hepatitis C
Wall Street is buzzing with anticipation about the first new all-oral drugs for hepatitis C approaching the market. The high rate of HCV infection and dissatisfaction with current treatments have created a potential multi-billion dollar bonanza for drug companies. It’s estimated that Gilead, the frontrunner in this race, will charge as much as $90,000 per … Continue reading “How to Save $200 Billion and Cure Hepatitis C”